Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability